RSS Feeds
Prophylaxis for Toxoplasmosis in AIDS
- Miles H. Beaman, MBBS;
- Benjamin J. Luft, MD; and
- Jack S. Remington, MD
-
Palo Alto Medical Foundation
Palo Alto, California 94301
Stanford University School of Medicine
Stanford, California 94305 -
State University of New York at Stony Brook
Stony Brook, New York 11794 -
Palo Alto Medical Foundation
Palo Alto, California 94301
Stanford University School of Medicine
Stanford, California 94305
Excerpt
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome (AIDS) may result in death even when treated (1). In patients with AIDS, toxoplasmic encephalitis is almost always a reactivation of a pre-existing latent infection (1), most often occurring when the total CD4 count falls below 100 cells/mm-3 (2). Persons at risk can be identified by screening human immunodeficiency virus (HlV)-positive patients for antibody to Toxoplasma gondii. Seroprevalence varies considerably in the general population, ranging from 96% in Western Europe to 10% to 40% in the United States (3). Of those patients with AIDS who are
Article and Author Information
-
Requests for Reprints: Jack S. Remington, MD, Department of Immunology and Infectious Disease, Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, Palo Alto, CA 94301.
-
Current Author Addresses: Drs. Beaman and Remington: Department of Immunology and Infectious Disease, Research Institute, Palo Alto Medical Foundation, 860 Bryant Street, Palo Alto, CA 94301. Dr. Luft: State University of New York at Stony Brook, Stony Brook, NY 11794.
